Libi Anandi Viswanathan

Dr. Libi Anandi Viswanathan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2014 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
DJDeepak R. Jain
Deepak R. Jain
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
MLMayurika Lahiri
Mayurika Lahiri
KGKrishna N. Ganesh
Krishna N. Ganesh

3 November 2015 in Oncology Reports
Verified
Journal Article
Closed access
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
KAK.A. Ashiq
K.A. Ashiq
KNK. Nitheesh
K. Nitheesh
MLMayurika Lahiri
Mayurika Lahiri
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

24 April 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SBSatish Bodakuntla
Satish Bodakuntla
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
SSSurojit Sural
Surojit Sural
PTPrasad Trivedi
Prasad Trivedi
MLMayurika Lahiri
Mayurika Lahiri
The DNA damage checkpoint signalling cascade sense damaged DNA and coordinates cell cycle arrest, DNA repair, and/or apoptosis. However, it is still not well understood how the signalling system differentiates between different kinds of DNA damage. N-nitroso-N-ethylurea (NEU), a DNA ethylating agent induces both transversions and transition mutations.

1 November 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
VCVaishali Chakravarty
Vaishali Chakravarty
KAK. A. Ashiq
K. A. Ashiq
SBSatish Bodakuntla
Satish Bodakuntla
MLMayurika Lahiri
Mayurika Lahiri
DNA alkylating agents form the first line of cancer chemotherapy. They not only kill cells but also behave as potential carcinogens. MNU, a DNA methylating agent, is well known to induce mammary tumours in rodents. However, the mechanism of tumorigenesis is not well understood. Our study reports a novel role played by DNA-dependent protein kinase (DNA-PK) in methylation damage-induced transformation using three-dimensional breast acinar cultures. Here, we report that exposure of breast epithelial cells to MNU inhibited polarisation at the basolateral domain, increased dispersal of the Golgi at the apical domain and induced an epithelial-to-mesenchymal transition (EMT)-like phenotype as well as invasion. This altered Golgi phenotype correlated with impaired intracellular trafficking. Inhibition of DNA-PK resulted in almost complete reversal of the altered Golgi phenotype and partial rescue of the polarity defect and EMT-like phenotype. The results confirm that methylation damage-induced activation of DNA-PK is a major mechanism in mediating cellular transformation. This article has an associated First Person interview with the first author of the paper.

7 December 2017 in ACS Omega
Verified
Journal Article
Open access
SPSandeep Palvai
Sandeep Palvai
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
SSSujit Sarkar
Sujit Sarkar
MAMeera Augustus
Meera Augustus
SRSudip Roy
Sudip Roy
SBSudipta Basu
Sudipta Basu
Breast cancer is the most devastating disease among females globally. Conventional chemotherapeutic regimen relies on the use of highly cytotoxic drugs as monotherapy and combination therapy leading to severe side effects to the patients as collateral damage. Moreover, combining hydrophobic and hydrophilic drugs create erratic biodistribution and suboptimal medicinal outcome. Hence, packaging multiple drugs of diverse mechanisms of action and biodistribution for safe delivery into tumor tissues with optimal dosages is indispensable for next-generation breast cancer therapy. To address these, in this report, we describe a unique cisplatin-triggered self-assembly of linear polymer into 3D-spherical sub 200 nm particles. These nanoparticles comprise a hydrophobic (paclitaxel) and hydrophilic drug (cisplatin) simultaneously in a single particle. Molecular dynamics simulation revealed hydrophilic–hydrophilic interaction and interchain H-bonding as underlying mechanisms of self-assembly. Confocal microscopy studies evidently demonstrated that these novel nanoparticles can home into lysosomes in breast cancer cells, fragment subcellular nuclei, and prevent cell division, leading to improved breast cancer cell death compared to free drug combination. Moreover, 3D-breast tumor spheroids were reduced remarkably by the treatment of these nanoparticles within 24 h. These dual-drug-loaded self-assembled polymeric nanoparticles have prospective to be translated into a clinical strategy for breast cancer patients.

1 August 2021 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
LJLibuše Janská
Libuše Janská
LVLibi Anandi Viswanathan
Libi Anandi Viswanathan
NKNell C. Kirchberger
Nell C. Kirchberger
ZMZoran S. Marinkovic
Zoran S. Marinkovic
LSLogan T. Schachtner
Logan T. Schachtner
CCCarlos Carmona-Fontaine
Carlos Carmona-Fontaine
There is an urgent need for accurate, scalable and cost-efficient models of the tumor microenvironment. Here, we detail how to fabricate and use the metabolic microenvironment chamber (MEMIC) – a 3D-printed ex vivo model of intratumoral heterogeneity. A major driver of the cellular and molecular diversity in tumors is accessibility to the blood stream. Whereas perivascular tumor cells have direct access to oxygen and nutrients, cells further from the vasculature must survive under progressively more ischemic environments. The MEMIC simulates this differential access to nutrients, allow co-culturing any number of cell types, and it is optimized for live imaging and other microscopy-based analyses. Owing to a modular design and full experimental control, the MEMIC provides insights into the tumor microenvironment that would be difficult to obtain via other methods. As proof of principle, we show that cells sense gradual changes in metabolite concentration leading to predictable molecular and cellular spatial patterns. We propose the MEMIC as a complement to standard in vitro and in vivo experiments, diversifying the tools available to accurately model, perturb and monitor the tumor microenvironment.